CN110891575A - 治疗和/或预防光化性角化病的方法 - Google Patents

治疗和/或预防光化性角化病的方法 Download PDF

Info

Publication number: CN110891575A
Authority: CN; China
Prior art keywords: days; subject; administered; day; area
Prior art date: 2017-03-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201880029861.9A

Other languages

English (en)

Chinese (zh)

Inventor

M-F.R.关

J.Y-N.刘

E.D.克莱默

D.L.卡特勒

J.方

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Anzix Special Purpose Co ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-03-10

Filing date

2018-03-12

Publication date

2020-03-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63446658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110891575(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-03-12 Application filed by Individual filed Critical Individual

2020-03-17 Publication of CN110891575A publication Critical patent/CN110891575A/zh

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 168
208000009621 actinic keratosis Diseases 0.000 title claims abstract description 142
238000011282 treatment Methods 0.000 claims description 156
230000000694 effects Effects 0.000 claims description 35
206010040914 Skin reaction Diseases 0.000 claims description 33
210000004761 scalp Anatomy 0.000 claims description 31
230000035483 skin reaction Effects 0.000 claims description 28
231100000430 skin reaction Toxicity 0.000 claims description 28
230000000699 topical effect Effects 0.000 claims description 26
230000002411 adverse Effects 0.000 claims description 24
230000002354 daily effect Effects 0.000 claims description 24
210000000245 forearm Anatomy 0.000 claims description 20
230000008961 swelling Effects 0.000 claims description 13
230000003810 hyperpigmentation Effects 0.000 claims description 12
208000000069 hyperpigmentation Diseases 0.000 claims description 11
206010037888 Rash pustular Diseases 0.000 claims description 10
208000029561 pustule Diseases 0.000 claims description 10
208000003367 Hypopigmentation Diseases 0.000 claims description 9
208000003251 Pruritus Diseases 0.000 claims description 9
208000025865 Ulcer Diseases 0.000 claims description 9
230000003628 erosive effect Effects 0.000 claims description 9
210000001508 eye Anatomy 0.000 claims description 9
210000001061 forehead Anatomy 0.000 claims description 9
210000004247 hand Anatomy 0.000 claims description 9
230000003425 hypopigmentation Effects 0.000 claims description 9
230000015572 biosynthetic process Effects 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 8
230000036269 ulceration Effects 0.000 claims description 8
230000007332 vesicle formation Effects 0.000 claims description 8
206010019233 Headaches Diseases 0.000 claims description 7
231100000869 headache Toxicity 0.000 claims description 7
210000002414 leg Anatomy 0.000 claims description 7
210000000088 lip Anatomy 0.000 claims description 7
210000005010 torso Anatomy 0.000 claims description 7
206010003051 Application site pain Diseases 0.000 claims description 6
208000002193 Pain Diseases 0.000 claims description 6
210000000617 arm Anatomy 0.000 claims description 6
210000005069 ears Anatomy 0.000 claims description 6
210000003739 neck Anatomy 0.000 claims description 6
210000001331 nose Anatomy 0.000 claims description 6
230000003442 weekly effect Effects 0.000 claims description 6
206010030113 Oedema Diseases 0.000 claims description 5
206010068319 Oropharyngeal pain Diseases 0.000 claims description 5
210000000744 eyelid Anatomy 0.000 claims description 5
210000002683 foot Anatomy 0.000 claims description 5
230000007803 itching Effects 0.000 claims description 5
201000009240 nasopharyngitis Diseases 0.000 claims description 5
230000036407 pain Effects 0.000 claims description 5
201000003004 ptosis Diseases 0.000 claims description 5
206010049041 Application site infection Diseases 0.000 claims description 3
206010003046 Application site irritation Diseases 0.000 claims description 3
206010003053 Application site pruritus Diseases 0.000 claims description 3
206010053424 Application site swelling Diseases 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
230000007794 irritation Effects 0.000 claims description 3
206010006784 Burning sensation Diseases 0.000 claims description 2
230000035807 sensation Effects 0.000 claims description 2
208000023409 throat pain Diseases 0.000 claims 2
230000003203 everyday effect Effects 0.000 claims 1
230000003902 lesion Effects 0.000 description 77
239000003814 drug Substances 0.000 description 22
VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 description 18
229940079593 drug Drugs 0.000 description 18
VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 18
229940107670 picato Drugs 0.000 description 18
206010015150 Erythema Diseases 0.000 description 12
206010042674 Swelling Diseases 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
230000037390 scarring Effects 0.000 description 9
238000012216 screening Methods 0.000 description 9
239000002131 composite material Substances 0.000 description 8
231100000321 erythema Toxicity 0.000 description 8
210000002381 plasma Anatomy 0.000 description 8
230000036470 plasma concentration Effects 0.000 description 8
206010041823 squamous cell carcinoma Diseases 0.000 description 8
VEBVPUXQAPLADL-UHFFFAOYSA-N Ingenol Natural products C1=C(CO)C(O)C2(O)C(O)C(C)=CC32C(C)CC2C(C)(C)C2C1C3=O VEBVPUXQAPLADL-UHFFFAOYSA-N 0.000 description 7
VEBVPUXQAPLADL-POYOOMFHSA-N ingenol Chemical compound C1=C(CO)[C@@H](O)[C@]2(O)[C@@H](O)C(C)=C[C@]32[C@H](C)C[C@H]2C(C)(C)[C@H]2[C@H]1C3=O VEBVPUXQAPLADL-POYOOMFHSA-N 0.000 description 7
238000011200 topical administration Methods 0.000 description 7
206010004146 Basal cell carcinoma Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000011156 evaluation Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
206010040844 Skin exfoliation Diseases 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
230000035618 desquamation Effects 0.000 description 5
229960002949 fluorouracil Drugs 0.000 description 5
230000009467 reduction Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
230000006641 stabilisation Effects 0.000 description 5
238000011105 stabilization Methods 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 4
208000000453 Skin Neoplasms Diseases 0.000 description 4
238000000315 cryotherapy Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
238000002428 photodynamic therapy Methods 0.000 description 4
201000000849 skin cancer Diseases 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
241000282414 Homo sapiens Species 0.000 description 3
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
201000007100 Pharyngitis Diseases 0.000 description 3
208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
206010059516 Skin toxicity Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
238000010171 animal model Methods 0.000 description 3
238000001574 biopsy Methods 0.000 description 3
239000006071 cream Substances 0.000 description 3
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
229960001259 diclofenac Drugs 0.000 description 3
230000007717 exclusion Effects 0.000 description 3
DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 3
229960002751 imiquimod Drugs 0.000 description 3
238000002483 medication Methods 0.000 description 3
MCVVUJPXSBQTRZ-ONEGZZNKSA-N methyl (e)-but-2-enoate Chemical compound COC(=O)\C=C\C MCVVUJPXSBQTRZ-ONEGZZNKSA-N 0.000 description 3
238000011002 quantification Methods 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
231100000438 skin toxicity Toxicity 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
208000019750 Administration site reaction Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010015995 Eyelid ptosis Diseases 0.000 description 2
206010020649 Hyperkeratosis Diseases 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
206010028372 Muscular weakness Diseases 0.000 description 2
201000002481 Myositis Diseases 0.000 description 2
206010041101 Small intestinal obstruction Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000002681 cryosurgery Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
229960002297 fenofibrate Drugs 0.000 description 2
210000003128 head Anatomy 0.000 description 2
230000036541 health Effects 0.000 description 2
230000001329 hyperkeratotic effect Effects 0.000 description 2
230000001969 hypertrophic effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000009533 lab test Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002547 new drug Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
238000013105 post hoc analysis Methods 0.000 description 2
238000009597 pregnancy test Methods 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000012552 review Methods 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000002562 urinalysis Methods 0.000 description 2
ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
206010056951 Actinic cheilitis Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010003055 Application site reaction Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010039580 Scar Diseases 0.000 description 1
206010040865 Skin hyperpigmentation Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
206010046306 Upper respiratory tract infection Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229960005339 acitretin Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001280 alpha hydroxy acids Chemical class 0.000 description 1
229960002749 aminolevulinic acid Drugs 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000005667 attractant Substances 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001277 beta hydroxy acids Chemical class 0.000 description 1
229960002938 bexarotene Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000002565 electrocardiography Methods 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
230000035558 fertility Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
238000009802 hysterectomy Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229960005280 isotretinoin Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
208000011873 mild conjunctivitis Diseases 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100001079 no serious adverse effect Toxicity 0.000 description 1
231100001099 no skin toxicity Toxicity 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000009806 oophorectomy Methods 0.000 description 1
239000000697 oral hormonal contraceptive Substances 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
210000004623 platelet-rich plasma Anatomy 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
208000037922 refractory disease Diseases 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
-1 salt compound Chemical class 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000009810 tubal ligation Methods 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000007879 vasectomy Methods 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)

CN201880029861.9A 2017-03-10 2018-03-12 治疗和/或预防光化性角化病的方法 Pending CN110891575A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201762469889P	2017-03-10	2017-03-10
US62/469,889		2017-03-10
PCT/US2018/021929 WO2018165647A1 (fr)	2017-03-10	2018-03-12	Méthodes de traitement et/ou de prévention de la kératose actinique

Publications (1)

Publication Number	Publication Date
CN110891575A true CN110891575A (zh)	2020-03-17

Family

ID=63446658

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201880029861.9A Pending CN110891575A (zh)	2017-03-10	2018-03-12	治疗和/或预防光化性角化病的方法

Country Status (13)

Country	Link
US (3)	US10617693B2 (fr)
EP (1)	EP3592355A4 (fr)
JP (3)	JP7502863B2 (fr)
KR (2)	KR20190141661A (fr)
CN (1)	CN110891575A (fr)
AU (2)	AU2018231144B2 (fr)
BR (1)	BR112019018687A2 (fr)
CA (1)	CA3055938A1 (fr)
IL (1)	IL269182B2 (fr)
MX (2)	MX387658B (fr)
TW (1)	TWI841523B (fr)
WO (1)	WO2018165647A1 (fr)
ZA (1)	ZA202100106B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2025077886A1 (fr) *	2023-10-13	2025-04-17	恩康药业科技（广州）有限公司	Composé et procédé de traitement et/ou de prévention de la kératose actinique

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7968574B2 (en) *	2004-12-28	2011-06-28	Kinex Pharmaceuticals, Llc	Biaryl compositions and methods for modulating a kinase cascade
BR112019018687A2 (pt) *	2017-03-10	2020-04-07	Athenex Inc	métodos de tratamento e/ou prevenção da ceratose actínica
CN111278808B (zh)	2017-09-07	2024-04-26	安兹克斯特殊目的有限责任公司	2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
WO2019173533A1 (fr) *	2018-03-07	2019-09-12	Athenex HK Innovative Limited	Compositions et méthodes de traitement des troubles cutanés hyperprolifératifs
JP7296945B2 (ja) *	2018-03-28	2023-06-23	テルモ株式会社	医療デバイス
JP2022535267A (ja) *	2019-06-05	2022-08-05	アセネックスインコーポレイテッド	乾癬を治療および／または予防する方法
AU2022209830A1 (en) *	2021-01-21	2023-08-03	Sirnaomics, Inc.	Compositions and methods for treatment of skin cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110021555A1 (en) *	2008-12-19	2011-01-27	Graceway Pharmaceuticals, Llc	Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7968574B2 (en)	2004-12-28	2011-06-28	Kinex Pharmaceuticals, Llc	Biaryl compositions and methods for modulating a kinase cascade
EP1836169B9 (fr)	2004-12-28	2012-07-04	Kinex Pharmaceuticals, LLC	Compositions et procédés de traitement de troubles impliquant une prolifération cellulaire
JP5564251B2 (ja)	2006-06-29	2014-07-30	キネックスファーマシューティカルズ，エルエルシー	キナーゼカスケードを調節するためのビアリール組成物および方法
US7538252B2 (en) *	2006-09-05	2009-05-26	Bipar Sciences, Inc.	Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
US7939529B2 (en)	2007-05-17	2011-05-10	Kinex Pharmaceuticals, Llc	Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh)	2006-12-28	2014-10-21	Kinex Pharmaceuticals Llc	調節激酶級聯之組成物及方法
US7935697B2 (en)	2006-12-28	2011-05-03	Kinex Pharmaceuticals, Llc	Compositions for modulating a kinase cascade and methods of use thereof
WO2008144045A1 (fr)	2007-05-17	2008-11-27	Kinex Pharmaceuticals, Llc	Procédé pour la préparation de compositions pour moduler une cascade de kinases et procédé d'utilisation de celui-ci
EP2143421A1 (fr)	2008-07-07	2010-01-13	Almirall Hermal GmbH	Composition topique pour le traitement de la kératose actinique
US8741857B1 (en) *	2012-01-30	2014-06-03	Lawrence Moy	Treatments for actinic keratoses
NZ606177A (en) *	2012-01-30	2014-03-28	Dolorgiet Gmbh & Co Kg	Compositions for the treatment of actinic keratosis
KR20150034209A (ko)	2012-06-26	2015-04-02	델 마 파마슈티컬스 인코포레이티드	디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
BR112019018687A2 (pt) *	2017-03-10	2020-04-07	Athenex Inc	métodos de tratamento e/ou prevenção da ceratose actínica

2018
- 2018-03-12 BR BR112019018687A patent/BR112019018687A2/pt not_active Application Discontinuation
- 2018-03-12 TW TW107108242A patent/TWI841523B/zh active
- 2018-03-12 KR KR1020197029678A patent/KR20190141661A/ko not_active Ceased
- 2018-03-12 WO PCT/US2018/021929 patent/WO2018165647A1/fr not_active Ceased
- 2018-03-12 AU AU2018231144A patent/AU2018231144B2/en active Active
- 2018-03-12 IL IL269182A patent/IL269182B2/en unknown
- 2018-03-12 CN CN201880029861.9A patent/CN110891575A/zh active Pending
- 2018-03-12 EP EP18764980.1A patent/EP3592355A4/fr active Pending
- 2018-03-12 US US15/918,100 patent/US10617693B2/en active Active
- 2018-03-12 KR KR1020247017149A patent/KR20240090837A/ko active Pending
- 2018-03-12 JP JP2019549396A patent/JP7502863B2/ja active Active
- 2018-03-12 MX MX2019010707A patent/MX387658B/es unknown
- 2018-03-12 CA CA3055938A patent/CA3055938A1/fr active Pending
2019
- 2019-09-09 MX MX2021013354A patent/MX2021013354A/es unknown
2020
- 2020-02-28 US US16/804,092 patent/US11497750B2/en active Active
2021
- 2021-01-07 ZA ZA2021/00106A patent/ZA202100106B/en unknown
2022
- 2022-10-11 US US17/963,502 patent/US20230172942A1/en active Pending
- 2022-11-11 JP JP2022180723A patent/JP2023015269A/ja active Pending
2024
- 2024-03-20 AU AU2024201828A patent/AU2024201828A1/en active Pending
- 2024-11-28 JP JP2024207319A patent/JP2025029010A/ja active Pending

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110021555A1 (en) *	2008-12-19	2011-01-27	Graceway Pharmaceuticals, Llc	Lower dosage strength imiquimod formulations and shorter dosing regimens for treating actinic keratoses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KINEX PHARMACEUTICALS: "Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA)", 《HTTPS://WWW.PRNEWSWIRE.COM/NEWS- RELEASES/KINEX-PHARMACEUTICALS-ANNOUNCES-ALLOWANCE-OF-THE-INVESTIGATIONAL-NEW-DRUG-IND-APPLICATION-FOR-KX2-391-OINTMENT-BY-THE-UNITED-STATES-FOOD-AND-DRUG-ADMINISTRATION-FDA-268466522.HTML》 *
赵文丽: "FDA 接受 KX2-391 软膏治疗光化性角化病的研究性新药申请", 《国际药学研究杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2025077886A1 (fr) *	2023-10-13	2025-04-17	恩康药业科技（广州）有限公司	Composé et procédé de traitement et/ou de prévention de la kératose actinique

Also Published As

Publication number	Publication date
MX2021013354A (es)	2021-11-18
US20180256589A1 (en)	2018-09-13
EP3592355A1 (fr)	2020-01-15
AU2018231144A1 (en)	2019-10-03
IL269182A (en)	2019-11-28
RU2019131757A3 (fr)	2021-05-31
BR112019018687A2 (pt)	2020-04-07
JP7502863B2 (ja)	2024-06-19
KR20240090837A (ko)	2024-06-21
US11497750B2 (en)	2022-11-15
WO2018165647A1 (fr)	2018-09-13
IL269182B2 (en)	2023-11-01
ZA202100106B (en)	2022-08-31
MX387658B (es)	2025-03-18
IL269182B1 (en)	2023-07-01
JP2020510042A (ja)	2020-04-02
US10617693B2 (en)	2020-04-14
KR20190141661A (ko)	2019-12-24
CA3055938A1 (fr)	2018-09-13
JP2025029010A (ja)	2025-03-05
US20230172942A1 (en)	2023-06-08
RU2019131757A (ru)	2021-04-12
EP3592355A4 (fr)	2021-01-06
AU2024201828A1 (en)	2024-05-02
US20200197405A1 (en)	2020-06-25
TW201842913A (zh)	2018-12-16
TWI841523B (zh)	2024-05-11
MX2019010707A (es)	2020-01-15
AU2018231144B2 (en)	2023-12-21
JP2023015269A (ja)	2023-01-31

Publication	Publication Date	Title
US20230172942A1 (en)	2023-06-08	Methods of treating and/or preventing actinic keratosis
CN105792829A (zh)	2016-07-20	使用伊维菌素治疗丘疹脓疱性红斑痤疮
BR112015011673B1 (pt)	2021-03-09	composição e uso da mesma
US9713608B2 (en)	2017-07-25	Method for topically treating actinic keratosis on the trunk (except chest) or extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
Liu et al.	2020	Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled phase 4 trial
JP3830963B2 (ja)	2006-10-11	乾癬治療
RU2805929C2 (ru)	2023-10-24	Способы лечения и/или предотвращения актинического кератоза
BR122025000862A2 (pt)	2025-04-24	Usos do composto kx-01 no tratamento e/ou prevenção da ceratose actínica
TW202112379A (zh)	2021-04-01	治療及／或預防乾癬之方法
KR20180073686A (ko)	2018-07-02	국소 댑손 조성물을 사용하는 심상성 여드름의 치료 방법
Abbas et al.	2025	The role of antimetabolite medication compared with traditional technique (cryotherapy) for treatment of verrucae
TWI418347B (zh)	2013-12-11	治療疱疹病毒感染的方法
Dermotoi	0	Therapeutics 45
Yu et al.	2004	Pharmacokinetic profile of oral tazarotene1

Legal Events

Date	Code	Title	Description
2020-03-17	PB01	Publication
2020-03-17	PB01	Publication
2020-04-10	SE01	Entry into force of request for substantive examination
2020-04-10	SE01	Entry into force of request for substantive examination
2020-05-15	CB03	Change of inventor or designer information
2020-05-15	CB03	Change of inventor or designer information	Inventor after: Guan Mianfen Inventor after: Liu Yaonan Inventor after: E. D. Kramer Inventor after: D.L. Cutler Inventor after: Fang Rongsheng Inventor before: M-F.R.Guan Inventor before: J.Y-N.Liu Inventor before: E. D. Kramer Inventor before: D.L. Cutler Inventor before: J.Fang
2023-04-25	TA01	Transfer of patent application right
2023-04-25	TA01	Transfer of patent application right	Effective date of registration: 20230413 Address after: New York, United States Applicant after: Anzix Special Purpose Co.,Ltd. Address before: New York, United States Applicant before: Abbott

CN110891575A - 治疗和/或预防光化性角化病的方法 - Google Patents

Info

Links

Images

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=63446658

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (7)

Citations (1)

Family Cites Families (13)

Patent Citations (1)

Non-Patent Citations (2)

Cited By (1)

Also Published As

Similar Documents

Legal Events